Why the study?
Does ACE2 gene therapy improve glycemic control and prevent β-cell dysfunction in diabetic mice?
Does ACE2 gene therapy improve glycemic control and prevent β-cell dysfunction in diabetic mice?
ACE2 represents a novel therapeutic target for preventing β-cell dysfunction and improving glycemic control in type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
ACE2 merits exploration as a diabetes target; hypothesis-generating in mice, human translation untested.
Bindom et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: